High-density lipoprotein cholesterol to apolipoprotein A1 ratio and all-cause mortality among incident peritoneal dialysis patients. 2021

Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, 330006, China.

The ratio of high-density lipoprotein cholesterol to apolipoprotein A1 (HAR) is associated with all-cause mortality in nonchronic kidney disease patients, but its role in predicting all-cause mortality in patients undergoing peritoneal dialysis (PD) is still unclear. The purpose of this study was to investigate the relationship between HAR and all-cause mortality in patients with PD. The medical records of 1199 patients with PD from November 1, 2005, to August 31, 2019, were collected retrospectively. The main outcome was defined as all-cause mortality. The HAR was divided into three groups by X-tile software. The association between HAR and all-cause mortality was evaluated by Cox models. The Kaplan-Meier method was used for the survival curve. The median follow-up period was 35 months (interquartile range: 20-57 months), with a total of 326 deaths recorded. After multiple adjustments, the risk of all-cause mortality in the high HAR group was 1.96-fold higher than that in the low HAR group (hazard ratio: 1.96; 95% CI, 1.22 to 3.15; P = 0.005). The restricted cubic splines showed that the risk of all-cause mortality increased gradually when HAR was >0.37. In the stratified analysis, a high HAR was linked to a high risk of all-cause mortality in males, patients under 55 years old, and patients without diabetes or cardiovascular disease (CVD). This study suggests that HAR is independently related to all-cause mortality in PD patients, especially in males, patients under 55 years old, and patients without diabetes or CVD.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010530 Peritoneal Dialysis Dialysis fluid being introduced into and removed from the peritoneal cavity as either a continuous or an intermittent procedure. Dialyses, Peritoneal,Dialysis, Peritoneal,Peritoneal Dialyses
D002423 Cause of Death Factors which produce cessation of all vital bodily functions. They can be analyzed from an epidemiologic viewpoint. Causes of Death,Death Cause,Death Causes
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016632 Apolipoprotein A-I The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE. Apo A-I,Apo A-1,Apo A-I Isoproteins,Apo A1,Apo AI,ApoA-1,ApoA-I,Apolipoprotein A-1,Apolipoprotein A-I Isoprotein-2,Apolipoprotein A-I Isoprotein-4,Apolipoprotein A-I Isoproteins,Apolipoprotein A1,Apolipoprotein AI,Apolipoprotein AI Propeptide,Pro-Apo A-I,Pro-Apolipoprotein A-I,Proapolipoprotein AI,Apo A I Isoproteins,Apolipoprotein A 1,Apolipoprotein A I,Apolipoprotein A I Isoprotein 2,Apolipoprotein A I Isoprotein 4,Apolipoprotein A I Isoproteins,Pro Apo A I,Pro Apolipoprotein A I

Related Publications

Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
December 2021, Nutrients,
Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
January 2021, Journal of clinical lipidology,
Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
February 2021, Nutrition, metabolism, and cardiovascular diseases : NMCD,
Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
December 2024, Renal failure,
Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
June 2021, Nutrition, metabolism, and cardiovascular diseases : NMCD,
Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
October 2022, International urology and nephrology,
Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
August 2019, The Journal of clinical endocrinology and metabolism,
Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
April 2015, Heart (British Cardiac Society),
Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
January 2017, Kidney & blood pressure research,
Chuanfei Zeng, and Caixia Yan, and Shan Guo, and Hengmei Zhu, and Yanbing Chen, and Xiaojiang Zhan
November 2019, Lipids in health and disease,
Copied contents to your clipboard!